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Predictors of Squamous Cell Carcinoma in High-Risk
Patients in the VATTC Trial
Michael Y. Xiong1,2, Amilcar E. Rizzo1, Tobias S.D. Cohen3, Robert K. Dyer2, Kaveri Korgavkar1,2,
Stephen F. Bingham4 and Martin A. Weinstock1,2,5 for the Veterans Affairs Topical Tretinoin Chemoprevention
(VATTC) Trial Group6
Invasive squamous cell carcinoma (SCC) of the skin is one of the most common cancers in the United States, with
no proven means for prevention other than systemic retinoids, which have significant toxicity, and sunscreen. We
sought to determine the risk factors for invasive SCC on the face or ears in a high-risk population comprising
1,131 veterans in the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial. Participants were required
to have been diagnosed with at least two keratinocyte carcinomas (KCs) in the 5 years prior to enrollment. The
median duration of follow-up was 3.7 years. Twenty-three percent of the participants developed a new invasive
SCC, and the cumulative risk of invasive SCC was 30% at 5 years. The following factors independently predicted
for new invasive SCCs: number of invasive SCCs and number of in situ SCCs in the 5 years prior to enrollment,
actinic keratoses count at enrollment, a history of ever use of topical 5-fluorouracil, and total occupational time
spent outdoors. In contrast, the use of angiotensin-convering enzyme inhibitors or angiotensin receptor blockers
during the study and a history of warts anywhere on the body were found to protect against new invasive SCCs.
These independent predictors remained the same for all SCCs (invasive and in situ combined). The number of
basal cell carcinomas in the 5 years prior to enrollment, sunburns, sun sensitivity, and recreational sun exposure
were not associated with new SCCs. These findings identify key risk factors for additional SCCs in patients with
multiple prior KCs, and suggest that a history of warts may be associated with reduced SCC risk.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC) and basal cell
carcinoma (BCC) are the most common malignancies in the
United States (Rogers et al., 2010). In particular, invasive SCC
is a significant health concern with no proven means for
prevention other than systemic retinoids (Kraemer et al., 1988;
Bavinck et al., 1995; DiGiovanna, 1998; Kovach et al., 2006),
which have significant toxicity, and sunscreen (Green et al.,
1999). Although less common than BCCs, SCCs account for
the majority of deaths due to nonmelanoma skin cancer
(Weinstock, 1993; Lewis and Weinstock, 2004). The
incidence of SCC has continued to increase over the past
several decades, especially for older age groups (Weinstock,
1993; Miller and Weinstock, 1994; Karagas et al., 1999), a
trend that is also being seen worldwide (Gray et al., 1997;
Staples et al., 1998; Hannuksela-Svahn et al., 1999; Iversen
and Tretli, 1999). However, the exact incidence of SCC in the
United States is unknown because it is not reported to
cancer registries. The cumulative 3-year risk of subsequent
SCC in patients with a prior SCC is 18% (Marcil and Stern,
2000). Predisposing risk factors for SCC have been well
established, including increased sun exposure (Armstrong
and Kricker, 1996, 2001; English et al., 1998a; Suarez et al.,
2007), populations closer to the equator, occupational
exposure outdoors (Schmitt et al., 2011), and a history of
precancerous lesions, along with other factors (Kricker et al.,
1991, 1994; Gallagher et al., 1995; Grodstein et al., 1995;
Elwood and Gallagher, 1997; English et al., 1998b). Although
there is evidence demonstrating an enhanced risk of BCC
among individuals exposed to ionizing radiation, this does not
appear to be the case with SCC (Karagas et al., 1996; Ron
et al., 1998; Yoshinaga et al., 2005; Levi et al., 2006).
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Evidence for predictors of future SCCs in high-risk populations
have not been firmly established (Marcil and Stern, 2000). To
better define risk factors for future SCCs in a high-risk
population, we investigated predictors of SCC among
participants in the Veterans Affairs Topical Tretinoin
Chemoprevention (VATTC) Trial, who had at least two
keratinocyte carcinomas (KCs) in the 5 years before
enrollment.
RESULTS
A total of 1,131 participants were enrolled, most of whom
were men (97%). The median age of participants was 72
years. Participants in the study tended to have a history of
heavily sun-damaged skin, with an average of 3.6 KCs in the 5
years before randomization and an average of 7.3 actinic
keratoses (AKs) at baseline examination at start of the study.
The median duration of follow-up in years from the date of
randomization to the end of study or death, or withdrawal in
the cohort, was 3.7 years; 23% of study participants devel-
oped at least one new invasive SCC during the study period.
The 1, 3, and 5-year Kaplan–Meier estimates for development
of new invasive SCCs were 8, 22, and 30% respectively.
In univariable analyses, the most important predictors of
time to new invasive SCC (Po0.001) were the number of prior
invasive SCCs, number of prior in situ SCCs, number of AKs at
enrollment, history of ever use of 5-fluorouracil, occupational
sun exposure between 1000 and 1500 hours at ages over 30
years, total occupational sun exposure between 1000 and
1500 hours, total occupational time spent working outside
between 1000 and 1500 hours, and total lifetime sun exposure
(Table 1). Those in the highest quintiles for prior invasive SCCs
and AKs at baseline had hazard rate ratios (HRRs) that were
4.3 times higher (95% confidence interval (CI): 2.6–7.2) and
5.7 times higher (95% CI: 3.5–9.2), respectively, than those in
the lowest quintiles. On the other hand, the use of angioten-
sin-converting enzyme inhibitors (ACEis) or angiotensin recep-
tor blockers (ARBs) during the study was associated with
reduced risk of invasive SCCs. Sun sensitivity, history of
sunburns, recreational sun exposure, and latitude of residence
after teenage years were not significantly associated with new
SCCs based on univariable analyses.
For the multivariable model, we used backwards stepwise
regression to include variables that had a P-valueo0.15 in the
univariable analyses (Table 2). In addition, a forwards stepwise
regression analysis was performed to identify the strongest risk
factors for invasive SCC. Results from the forwards model
were identical to those of the backwards model. The most
important independent predictors for time to new invasive
SCC (Po0.001) were the number of invasive SCCs in the
5 years before enrollment (HRR: 3.04, 95% CI: 1.79–5.18) and
number of AKs at the start of the study (HRR: 3.07, 95% CI:
1.84–5.10). Other positive predictors included history of ever
use of 5-fluorouracil (HRR: 1.61, 95% CI: 1.10–2.22), a history
of in situ SCCs in the prior 5 years (HRR: 2.23, 95% CI: 1.27–
3.95), and total occupational time outside, defined as decades
spent working outdoors between 1000 and 1500 hours (HRR:
1.23, 95% CI: 1.08–1.39). In contrast, the use of either ACE
inhibitors or ARBs during the study was negatively associated
with time to new invasive SCC (HRR: 0.58, 95% CI: 0.41–
0.81). Collinearity tests revealed Pearson’s r-values to be less
than 0.29 (Table 3) and variance inflation factor values to be
less than 1.21 (Table 4).
We had several representations of sun exposure, including
total occupational time spent outdoors, total occupation sun
exposure, occupational sun exposure for ages over and under
30 years, and total lifetime sun exposure. Total lifetime sun
exposure was calculated as the sum of occupational, recrea-
tional, and vacation sun exposure. Although all of these risk
factors were statistically significant in the univariable analyses,
total occupational time outdoors was more strongly associated
with invasive SCC risk than any other representation.
In addition, we had four representations of sunscreen use,
including any sunscreen use on the face or ears 1 week before
enrollment and 6 months before enrollment, as well as sun
protection factorX15 use on the face or ears 1 week before
enrollment and 6 months before enrollment. As these variables
were highly collinear (all had variance inflation factors420),
we only included the variable with the lowest univariable
P-value into the multivariable analysis, which in this
case was any sunscreen use on the face or ears 1 week before
enrollment. Sunscreen use, however, was ultimately not
retained in the multivariable model.
The results for all SCCs (invasive and in situ combined) were
similar to those for invasive SCCs alone, in both the univari-
able and multivariable analyses (Tables 1 and 2).
DISCUSSION
We report a cohort study of a population at high risk of KCs,
who were followed for a median duration of 3.7 years for
occurrence of SCC on the face or ears. The most important
independent risk factors in this group were number of invasive
SCCs in the 5 years before enrollment, number of AKs at
enrollment, and total occupational time spent working out-
doors. In addition, the number of prior in situ SCCs and a
history of ever use of 5-fluorouracil were also strongly
associated with an increased risk of future SCCs. On the other
hand, the use of ACEi/ARB during the study and a history of
warts anywhere on the body were associated with reduced
risk of developing subsequent SCCs. After 5 years, study
participants had a 30% probability of developing a new
invasive SCC on the face or ears.
Strengths of this study include a large sample size in a high-
risk population from six locations in the United States, with a
mean follow-up duration of almost 4 years. Endpoints were
verified by electronic medical records for completeness of
obtained biopsies, and by central reference dermatopathology
reviews. Key predictor variables were also obtained by direct
observations (AKs) or by recorded reviews (prior KCs).
Limitations include a study population of veterans who
were primarily male, elderly Caucasians who had two or more
prior KCs, which may limit the generalizability of our results to
other groups. Index event bias may also be a limitation, as our
requirement for participants to have had two or more pre-
enrollment KCs will tend to shift results towards the null
(Dahabreh and Kent, 2011). This may explain why some
known risk factors for primary SCC, such as sun exposure,
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Table 1. Univariable predictors of SCC risk on face or ears
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
Sex 4.76 1.18–19.13 0.028 2.26 0.93–5.46 0.071
Male 1,097 (97)
Female 34 (3)
1,131
Age (in decades) 1.18 1.03–1.36 0.016 1.18 1.05–1.34 0.007
p59 158 (14) 1.00 1.00
60–69 304 (27) 1.45 1.58
70–79 505 (45) 1.90 1.90
X80 164 (15) 1.48 1.66
1,131
Education 0.94 0.74–1.21 0.648 0.91 0.73–1.14 0.415
No college 483 (43)
Some college or higher 648 (57)
1,131
BCCs in prior 5 years (0 to 1 scale) 1.05 0.71–1.55 0.813 0.99 0.69–1.41 0.962
0–1 (0) 204 (18)
2 (0.25) 439 (39)
3 (0.5) 200 (18)
4–5 (0.75) 159 (14)
X6 (1) 129 (11)
1,131
SCCs invasive in prior 5 years
(0 to 1 scale)
6.01 4.24–8.71 o0.001 5.22 3.72–7.33 o0.001
0 (0) 731 (65) 1.00 1.00
1 (0.25) 222 (20) 2.08 2.28
2 (0.5) 109 (10) 3.87 3.21
3 (0.75) 34 (3) 1.07 1.66
X4 (1) 35 (3) 4.31 2.17
1,131
AKs at baseline (0 to 1 scale) 4.59 3.23–6.52 o0.001 3.96 2.89–5.42 o0.001
0 (0) 269 (24) 1.00 1.00
1–2 (0.25) 252 (22) 2.29 2.18
3–6 (0.5) 236 (21) 3.41 3.09
7–14 (0.75) 181 (16) 4.86 4.39
X15 (1) 193 (17) 5.70 4.71
1,131
SCCs in situ in last 5 years (0 to 1 scale) 2.88 1.96–4.23 o0.001 3.06 2.16–4.34 o0.001
0 (0) 981 (87) 1.00 1.00
1 (0.5) 103 (9) 2.20 2.28
X2 (1) 47 (4) 2.42 2.56
1,131
Family history of skin cancer
(self-reported)1
0.92 0.70–1.21 0.555 0.95 0.74–1.21 0.667
Yes 307 (27)
No 824 (73)
1,131
Table 1 Continued on following page
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Table 1. (continued )
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
History of ever having eczema
(self-reported)1
0.53 0.25–1.11 0.093 0.88 0.50–1.53 0.644
Yes 52 (5)
No 1,079 (95)
1,131
Current smoker 1.37 1.01–1.86 0.040 1.17 0.88–1.56 0.277
Yes 183 (16)
No 948 (84)
1,131
Current or former smoker 0.85 0.65–1.11 0.226 0.83 0.65–1.05 0.128
Yes 812 (72)
No 319 (28)
1,131
Sunburn causing pain at ages p12 1.00 0.78–1.27 0.996 1.08 0.87–1.35 0.468
Yes 552 (49)
No 550 (49)
1,131
Sunburn causing pain at ages 13–17 1.01 0.79–1.29 0.925 1.09 0.88–1.37 0.420
Yes 477 (43)
No 627 (57)
1,104
Sunburn causing pain at ages X18 1.03 0.80–1.31 0.837 1.09 0.87–1.36 0.446
Yes 477 (43)
No 632 (57)
1,109
Sunburn causing pain in prior
5 years
0.68 0.33–1.37 0.275 0.86 0.48–1.52 0.597
Yes 46 (4)
No 1,066 (96)
1,112
History of ever using 5-FU (self-
reported)1
2.46 1.90–3.17 o0.001 2.20 1.73–2.78 o0.001
Yes 215 (19)
No 916 (81)
1,131
History of using ACEi/ARB during study2 0.65 0.51–0.84 0.001 0.60 0.48–0.76 o0.001
Yes 489 (47)
No 562 (53)
1,051
History of ever having warts anywhere
on body (self-reported)1
0.70 0.54–0.89 0.004 0.70 0.56–0.88 0.002
Yes 726 (66)
No 378 (34)
1,099
Sun Sensitivity Index (0 to 1 scale, see
Materials and Methods)
1.62 0.90–2.92 0.106 1.82 1.07–3.09 0.028
0.0–0.2 (0) 65 (6)
40.2–0.4 (0.25) 248 (22)
Table 1 Continued on following page
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Table 1. (continued )
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
40.4–0.6 (0.5) 354 (32)
40.6–0.8 (0.75) 330 (30)
40.8–1.0 (1) 118 (11)
1,115
Latitude of residence at ages p12 0.97 0.94–0.99 0.011 0.97 0.95–0.99 0.011
o25 8 (1)
25–35 304 (28)
435 784 (72)
1,096
Latitude of residence at ages 13–17 0.99 0.97–1.00 0.086 0.99 0.97–1.00 0.094
o25 24 (2)
25–35 318 (30)
435 733 (68)
1,075
Latitude of residence at ages X18 0.98 0.96–1.01 0.152 0.99 0.96–1.01 0.300
o25 15 (1)
25–35 504 (45)
435 594 (53)
1,113
Latitude of residence in prior 5 years 1.00 0.98–1.02 0.679 1.00 0.98–1.01 0.932
o25 23 (2)
25–35 731 (66)
435 357 (32)
1,111
Total occupational decades outdoors3 in
sun
1.30 1.19–1.42 o0.001 1.25 1.16–1.37 o0.001
0 93 (8)
p3 919 (83)
43 101 (9)
1,113
Total occupational decades outdoors3 1.25 1.16–1.36 o0.001 1.22 1.14–1.31 o0.001
0 92 (8)
p3 791 (71)
43 230 (21)
1,113
Total occupational decades outdoors3 in
sun at ages o30
1.21 1.01–1.46 0.037 1.10 0.93–1.31 0.271
0 89 (9)
p1 767 (76)
41 152 (15)
1,008
Total occupational decades outdoors3 in
sun at ages X30
1.38 1.20–1.58 o0.001 1.43 1.16–1.78 0.001
0 92 (11)
p1 386 (48)
41 328 (41)
806
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Table 1. (continued )
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
Total weeks on vacation4 1.11 0.82–1.50 0.514 1.18 0.91–1.55 0.213
0 913 (82)
X1 199 (18)
1,112
Total days outside3 on vacation4 1.11 0.82–1.50 0.514 1.18 0.91–1.55 0.213
0 913 (82)
X1 199 (18)
1,112
Total days in sun3 on vacation4 1.11 0.82–1.50 0.514 1.18 0.91–1.55 0.213
0 913 (82)
X1 199 (18)
1,112
Total days in sun3 on vacation4 without
wearing SPF 15 or greater
1.26 0.89–1.82 0.194 1.24 0.89–1.72 0.205
0 993 (89)
X1 118 (11)
1,111
Total recreational months outside3 at
ages p12
1.00 0.98–1.02 0.861 1.00 0.99–1.02 0.660
0 64 (6)
p12 669 (61)
412 357 (33)
1,090
Total recreational months outside3 at
ages 13–17
0.96 0.91–1.02 0.152 0.96 0.92–1.01 0.156
0 127 (12)
p12 955 (88)
412 4 (0)
1,086
Total recreational months outside3 at
ages 18–40
0.99 0.97–1.01 0.357 0.99 0.97–1.01 0.188
0 171 (16)
p12 713 (66)
412 196 (18)
1,080
Total recreational months outside3 in
prior 5 years
0.99 0.95–1.03 0.525 1.00 0.96–1.03 0.812
0 244 (23)
p12 801 (75)
412 23 (2)
1,068
Ethnicity of grandparents 0.75 0.57–0.98 0.037 0.85 0.67–1.08 0.187
1¼ Scandanavian/Celtic 1,183 (33)
1.5 193 (5)
2¼Northern European/Slavic 1,905 (53)
2.5 48 (1)
3¼Mediterranean/Middle Eastern/
Hispanic/Latin American/Native
American/Asian
245 (7)
Table 1 Continued on following page
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Table 1. (continued )
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
4¼African black 0 (0)
3,574
Days spent outside3 forX30 mins in
prior week (0 to 1 scale)
1.18 0.88–1.56 0.264 1.17 0.90–1.51 0.234
None (0) 352 (32)
Some (0.5) 256 (23)
All (1) 503 (45)
1,111
Days spent outside3 forX2 h in prior
week (0 to 1 scale)
1.18 0.89–1.57 0.246 1.18 0.92–1.53 0.199
None (0) 618 (56)
Some (0.5) 213 (19)
All (1) 280 (25)
1,111
Days spent outside3 forX30 min in prior
6 months (0 to 1 scale)
1.03 0.75–1.43 0.843 0.99 0.74–1.33 0.969
None (0) 222 (20)
Some (0.5) 437 (39)
All (1) 450 (41)
1,109
Days spent outside3 forX2 h in prior
6 months (0 to 1 scale)
0.99 0.72–1.35 0.927 0.99 0.75–1.32 0.965
None (0) 480 (43)
Some (0.5) 390 (35)
All (1) 239 (22)
1,109
Sunscreen use3 on face or ears in prior
week (0 to 1 scale)
1.42 1.08–1.88 0.013 1.44 1.12–1.85 0.005
Never (0) 616 (56)
Sometimes (0.5) 184 (17)
Always (1) 291 (27)
1,091
Sunscreen use3 on face or ears in prior
6 months (0 to 1 scale)
1.21 0.89–1.63 0.219 1.23 0.94–1.62 0.129
Never (0) 522 (47)
Sometimes (0.5) 320 (29)
Always (1) 259 (24)
1,101
SPFX15 use3 on face or ears
in prior week (0 to 1 scale)
1.32 0.99–1.74 0.055 1.36 1.06–1.76 0.017
Never (0) 630 (58)
Sometimes (0.5) 179 (16)
Always (1) 282 (26)
1,091
SPFX15 use3 on face or
ears in prior 6 months
(0 to 1 scale)
1.18 0.87–1.60 0.276 1.24 0.94–1.63 0.121
Never (0) 542 (49)
Sometimes (0.5) 312 (28%)
Always (1) 247 (22)
1,101
Table 1 Continued on following page
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were not found to be significant predictors in our model. In
addition, overfitting of the multivariable model is a concern, as
certain variables we tested, such as number of baseline AKs,
are along the causative pathway. Nonetheless, overfitting
seems unlikely to be substantial given our low variance
inflation factor and Pearson’s r-values, which
are all less than 1.21 and 0.29, respectively (Tables 3 and 4).
Finally, we cannot eliminate the possibility of error with
assessments, which are dependent on recall. However, recall
bias was minimized as many of the predictors, such as prior
KCs and baseline AKs, were measured by dermatological
examination or medical record review. Moreover, the pro-
spective ascertainment of these variables further helps in
preventing recall bias.
Previous SCCs (both invasive and in situ) have been shown
to be a risk factor for developing a new invasive SCC, and the
3-year risk of 22% that we noted is similar to prior reports
(Karagas, 1994; Marcil and Stern, 2000). There was no
association between previous BCCs and development of
new SCCs, whereas other studies have shown a weak
association (Marcil and Stern, 2000). We also did not find
an association between history of eczema and subsequent
SCC risk, although prior studies have suggested a link
Table 1. (continued )
Invasive SCC Invasiveþ in situ SCC
Predictor n (%) HRR 95% CI P-value HRR 95% CI P-value
Lifetime sun exposure in decades 2.47 1.67–3.66 o0.001 2.22 1.55–3.18 o0.001
p0.5 711 (64)
40.5 403 (36)
1,114
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AK, actinic keratose; BCC, basal cell carcinoma; CI,
confidence interval; HRR, hazard rate ratio; SCC, squamous cell carcinoma; SPF, sun protection factor; 5-FU, 5-fluorouracil.
1Data were self-reported, as records were not available beyond 5 years before study.
2Frequency is for invasive SCC. Similar frequency is seen for total SCC.
3During 1000–1500 hours.
4Between latitudes 251 N and 251 S.
Table 2. Multivariable predictors of SCC risk on face
or ears
Predictor HRR 95% CI P-value
Invasive SCCs
SCCs invasive in prior 5 years1 3.04 1.79–5.18 o0.001
SCCs in situ in prior 5 years2 2.23 1.27–3.95 0.006
AKs at baseline3 3.07 1.84–5.10 o0.001
History of ever using 5-FU4 1.61 1.10–2.36 0.014
History of using ACEi/ARB during study 0.58 0.41–0.81 0.001
History of ever having warts anywhere on
body4
0.69 0.49–0.97 0.034
Occupational time outdoors5 in decades 1.23 1.08–1.39 0.002
All SCCs (invasiveþ in situ)
SCCs invasive in prior 5 years1 2.90 1.82–4.62 o0.001
SCCs in situ in prior 5 years2 1.75 1.10–2.78 0.019
AKs at baseline3 2.60 1.72–3.94 o0.001
History of ever using 5-FU4 1.46 1.05–2.03 0.023
History of using ACEi/ARB during study 0.60 0.45–0.79 o0.001
History of ever having warts anywhere on
body4
0.72 0.54–0.95 0.020
Occupational time outdoors5 in decades 1.26 1.14–1.39 o0.001
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin receptor blocker; AKs, actinic keratoses; CI, confidence interval; HRR,
hazard rate ratio; SCC, squamous cell carcinoma; 5-FU, 5-fluorouracil.
1Categorical variable (0 to 1 scale): 0, no invasive SCCs; 0.25, 1 SCC; 0.5,
2 SCCs; 0.75, 3 SCCs; 1.0X4 SCCs.
2Categorical variable (0 to 1 scale): 0, no in situ SCCs; 0.5, 1 SCC; 1, X2
SCCs.
3Categorical variable (0 to 1 scale): 0, no AKs at beginning of study; 0.25,
1–2 AKs; 0.5, 3–6 AKs; 0.75, 7–14 AKs; 1.0, X15 AKs.
4Data were self-reported, as records were not available beyond 5 years
before study.
5During 1000–1500 hours.
Table 3. VIFs for multivariable predictors
Predictor VIF
SCCs invasive in prior 5 years1 1.21
SCCs in situ in prior 5 years2 1.10
AKs at baseline3 1.11
History of ever using 5-FU4 1.12
History of using ACEi/ARB during study 1.01
History of ever having warts anywhere on body4 1.00
Occupational time outdoors in decades5 1.02
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin receptor blocker; AKs, actinic keratoses; SCC, squamous cell
carcinoma; VIF, Variance inflation factors; 5-FU, 5-fluorouracil.
1Categorical variable (0 to 1 scale): 0, no invasive SCCs; 0.25, 1 SCC; 0.5,
2 SCCs; 0.75, 3 SCCs; 1.0, X4 SCCs.
2Categorical variable (0 to 1 scale): 0, no in situ SCCs; 0.5, 1 SCC; 1, X2
SCCs.
3Categorical variable (0 to 1 scale): 0, no AKs at beginning of study; 0.25,
1–2 AKs; 0.5, 3–6 AKs; 0.75, 7–14 AKs; 1.0, X15 AKs.
4Data were self-reported, as records not available beyond 5 years before
study.
5During 1000–1500 hours.
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between eczema and noncutaneous SCC (Duk et al., 1989;
Heinz et al., 2003), and cutaneous BCC (Dyer et al., 2012). In
addition, we did not find smoking to be associated with
subsequent SCC risk. Although some studies have shown
smoking to be a risk factor for SCC (Aubry and MacGibbon,
1985; Karagas et al., 1992), other studies have not (Green
et al., 1996; Odenbro et al., 2005).
The association between AKs at the start of the study and
time to new invasive SCC is extremely strong; indeed, AKs are a
precursor to SCCs (Marks et al., 1988; Green and Battistutta,
1990; Chen et al., 2005). Prior research has shown that SCCs
are associated with cumulative lifetime sun exposure (Marks
et al., 1988, 1990; Salasche, 2000), and our data confirm this.
Our multivariable model did not demonstrate any associations
between incidence of new invasive SCCs and residential
latitude, leisure time, or sun exposure during vacation
(Elwood et al., 1974) in this high-risk population, but it did
find an association with occupational time spent outside.
Previous studies have also demonstrated that the risk of SCC
is related to total occupational sun exposure (Armstrong and
Kricker, 2001), although these associations are not strong.
Being male and being older has been shown to increase
the risk of developing a new SCC, and in our study they were
significant on their own, but not when other factors were
included in the regression model. Only 3% of participants
were women.
We found the use of ACE inhibitors or ARBs to be associated
with reduced risk of SCCs, which has been previously demon-
strated (Christian et al., 2008). Other studies have also
suggested a link between ACEi/ARB use and reduced risk of
several types of cancers in humans (Lever et al., 1998), as well
as renal cell carcinoma in animal models (Hii et al., 1998).
The association between human papilloma virus (HPV) and
cutaneous nongenital/nonperianal SCC is based, in large part,
on inconsistent epidemiological studies on HPV–DNA serol-
ogies (Steger et al., 1990; Stark et al., 1998; Bouwes Bavinck
et al., 2000; Favre et al., 2000; Masini et al., 2003; Andersson
et al., 2008; Mammas et al., 2008; Waterboer et al., 2008;
Andersson et al., 2012). However, the link between a self-
reported history of warts and SCC development has not been
extensively studied. Kricker et al. (1991) found that a history of
ever having warts protected against BCC (odds ratio: 0.66,
P¼0.02) but not SCC. In another study, a history of warts
(odds ratio: 0.87, 95% CI: 0.57–1.32, P¼ 0.51) showed little
association with SCC (English et al., 1998b). However, we
found that the presence of a wart anywhere on the body at any
time in a subject’s life reduced the risk of a future SCC. Given
the ubiquity of HPV subtypes, a low-risk HPV subtype may
exist that also confers protection against SCC development.
One plausible explanation for this occurrence is the existence
of antagonistic interference between HPV subtypes, as has
been previously shown in cervical cancer (Silins et al., 1999).
Our observation of a history of warts and lower SCC risk calls
for independent confirmation.
For a large number of patients with a previous history of
invasive SCCs, our findings further support the need to
identify effective preventive measures in the high-risk
population. Our finding of a protective effect on SCC
development in patients with a history of warts demands
further investigation.
MATERIALS AND METHODS
A full description of study methods is described in previously
published reports from the VATTC Trial (Weinstock et al., 2001;
Jagdeo et al., 2007; Christian et al., 2008; Criscione et al., 2009; Dore
et al., 2009; Geng et al., 2009; Weinstock et al., 2009a, 2009b; Lee
et al., 2010; Lee and Weinstock, 2011; Nunes et al., 2011;
Baibergenova et al., 2012).
Table 4. Pearson’s correlation coefficients for multivariable predictors
SCCs
invasive in
prior 5 years1
SCCs in situ
in prior 5
years2
AKs at
baseline3
History of
ever using
5-FU4
History of using
ACEi/ARB during
study
History of ever
having warts
anywhere on body5
Occupational
time outdoors in
decades5
SCCs invasive in prior 5 years1 1.00
SCCs in situ in prior 5 years2 0.25 1.00
AKs at baseline3 0.28 0.14 1.00
History of ever using 5-FU4 0.29 0.20 0.19 1.00
History of using ACEi/ARB
during study
 0.05  0.07 0.01  0.03 1.00
History of ever having warts
anywhere on body4
0.00 0.04 0.02 0.03 0.01 1.00
Occupational time outdoors in
decades5
0.10 0.03 0.09 0.02 0.05  0.03 1.00
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AKs, actinic keratoses; SCC, squamous cell carcinoma;
5-FU, 5-fluorouracil.
1Categorical variable (0 to 1 scale): 0, no invasive SCCs; 0.25, 1 SCC; 0.5, 2 SCCs; 0.75, 3 SCCs; 1.0, X4 SCCs.
2Categorical variable (0 to 1 scale): 0, no in situ SCCs; 0.5, 1 SCC; 1, X2 SCCs.
3Categorical variable (0 to 1 scale): 0, no AKs at beginning of study; 0.25, 1–2 AKs; 0.5, 3–6 AKs; 0.75, 7–14 AKs; 1.0, X15 AKs.
4Data were self-reported, as records not available beyond 5 years prior to study.
5During 1000–1500 hours.
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The VATTC was a randomized, double-blind, vehicle-controlled,
multicenter study (ClinicalTrials.gov identifier: NCT00007631) with
participants enrolled from six VA medical centers: Durham, North
Carolina; Oklahoma City, Oklahoma; Chicago, Illinois; Long Beach,
California; Miami, Florida; and Phoenix, Arizona.
The study population consisted of VA patients who had been
diagnosed with at least two KCs (i.e., BCC or SCC) in the 5 years
before enrollment, excluding KCs in the genital and perianal areas.
Participants were required to be free of KCs at the beginning of the
study, which was verified by a study dermatologist. Participants were
excluded if they met any of the following criteria: systemic retinoid or
chemotherapy treatment within the 6 months before enrollment;
known allergy or severe past reaction to tretinoin; moderate to severe
dermatitis on the face; severe medical problems with very high 3-year
mortality risk, including but not limited to metastatic skin cancer,
other invasive cancer, and AIDS; special conditions predisposing to
KCs, including radiation therapy or scars from thermal burns to face
or ears, psoralen plus UVA treatment, organ transplant recipient,
arsenic exposure, basal cell nevus syndrome, mycosis fungoides, and
xeroderma pigmentosum; pregnant or nursing; or unlikely to comply
or not competent to give informed consent as judged by the study
investigator. Moreover, participants were excluded if they obtained
any of the following treatments 60 days before enrollment: topical 5-
fluorouracil or masoprocol, calcipotriene on the face or ears, topical
retinoids, or chemical peel or dermabrasion.
Participants were required to answer a baseline questionnaire to
ascertain information related to sun exposure, skin characteristics,
and other behaviors that have been linked to skin cancer develop-
ment (Table 1). They were then followed for 2–6 years, and obtained
a skin examination and interview every 6 months. Biopsies of any
suspicious lesions were taken at these 6-month intervals. The
diagnoses of all biopsies performed on study participants during the
trial were reviewed centrally by one of two reference study derma-
topathologists, whose diagnoses were considered definitive for study
purposes. Ten percent of specimens were reviewed by both study
dermatopathologists (Jagdeo et al., 2007).
Univariable analyses and the 1-, 3-, and 5-year risk of developing a
new invasive SCC were determined using Stata Version 8 statistical
software package (StataCorp LP, College Station, Texas), which
incorporates the Kaplan–Meier survivor function. The Cox propor-
tional hazards model was used to do determine the HRRs and 95%
CIs of a number of potential predictors of time to first new invasive
SCC. A multivariable model was then employed using stepwise
regression with those variables thought to be possible predictors of
time to first invasive SCC (all variables that had a Po0.15 in
univariable Cox regression), to determine whether they were inde-
pendent predictors for future SCCs. We repeated the above analyses
to determine the risk of developing all SCCs (both invasive and
in situ). Finally, we tested for collinearity using variance inflation
factor and Pearson’s correlation analyses to assess the possibility of
overfitting of the multivariable models.
This study was conducted in accordance with the Declaration of
Helsinki Principles, and all participants gave written, informed con-
sent. This study was approved by 17 committees: the Executive
Committee of the VA Topical Tretinoin Chemoprevention Trial, the
Study Data and Safety Monitoring Board, the Central Cooperative
Studies Program Coordinating Center Human Rights Committee, as
well as the institutional review boards and the research and
development committees of the six participating medical
centers and of the study chairman’s medical center (VA Medical
Center, Providence, Rhode Island). In addition, the Cooperative
Studies Evaluation Committee approved this study at the outset and
reviewed it at its midpoint.
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